Occurrence and removal of frequently prescribed pharmaceuticals and corresponding metabolites in wastewater of a sewage treatment plant

Science of the Total Environment

Volumn 532, Issue , 2015, Pages 762-770

  Gurke, Robert ^a   Rößler, Martin ^a   Marx, Conrad ^b   Diamond, Sam ^c   Schubert, Sara ^a   Oertel, Reinhard ^a   Fauler, Joachim ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c TRENT UNIVERSITY   (Canada)

Author keywords

Mass flow analysis; Metabolites; Pharmaceuticals; Removal rate; Sewage

Indexed keywords

AMIDES; BIOMOLECULES; DRUG PRODUCTS; EFFLUENT TREATMENT; EFFLUENTS; MASS TRANSFER; SEWAGE; SEWAGE TREATMENT PLANTS; WASTEWATER TREATMENT;

AVERAGE CONCENTRATION; HUMAN METABOLITES; MASS FLOW; MONITORING PERIODS; O-DESMETHYL VENLAFAXINE; REMOVAL RATE; SEWAGE TREATMENT PROCESS; URBAN SEWAGE TREATMENT;

METABOLITES;

CARBAMAZEPINE; CITALOPRAM; CLINDAMYCIN; DESVENLAFAXINE; DRUG METABOLITE; ENALAPRIL; EPROSARTAN; GABAPENTIN; LAMOTRIGINE; LICARBAZEPINE; LOSARTAN; METOPROLOL; N DESMETHYLCITALOPRAM; OXCARBAZEPINE; PREGABALIN; QUETIAPINE; TELMISARTAN; TOPIRAMATE; TRIAMTERENE; UNCLASSIFIED DRUG; VALSARTAN; DRUG; WASTE WATER; WATER POLLUTANT;

DRUG; EFFLUENT; EXCRETION; METABOLISM; METABOLITE; SEWAGE TREATMENT; WASTE FACILITY; WASTEWATER;

ARTICLE; DRUG DETERMINATION; ENVIRONMENTAL MONITORING; FLOW MEASUREMENT; INFLUENT; PRIORITY JOURNAL; SEWAGE EFFLUENT; SEWAGE TREATMENT PLANT; URBAN AREA; WASTE COMPONENT REMOVAL; WASTE WATER MANAGEMENT; WATER POLLUTANT; ANALYSIS; CHEMISTRY; SEWAGE; WASTE WATER;

ENVIRONMENTAL MONITORING; PHARMACEUTICAL PREPARATIONS; WASTE DISPOSAL, FLUID; WASTE WATER; WATER POLLUTANTS, CHEMICAL;

EID: 84932635327     PISSN: 00489697     EISSN: 18791026     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2015.06.067     Document Type: Article

References (41)

1. Besse J.-P., Kausch-Barreto C., Garric J. Exposure assessment of pharmaceuticals and their metabolites in the aquatic environment: application to the French situation and preliminary prioritization. Hum. Ecol. Risk Assess. An Int. J. 2008, 14:665-695. 10.1080/10807030802235078.
2. Brausch J.M., Connors K.A., Brooks B.W., Rand G.M. Human pharmaceuticals in the aquatic environment: a review of recent toxicological studies and considerations for toxicity testing. Rev. Environ. Contam. Toxicol. 2012, 218:1-99. 10.1007/97814614313741.
3. Chernick M.R. Bootstrap Methods: A Guide for Practitioners and Researchers 2008, John-Wiley & Sons, Hoboken, New Jersey, (9780471756217). 2nd ed.
4. Dain J.G., Nicoletti J., Ballard F. Biotransformation of clozapine in humans. Drug Metab. Dispos. 1997, 25:603-609.
5. Dalgaard L., Larsen C. Metabolism and excretion of citalopram in man: identification of O-acyl- and N-glucuronides. Xenobiotica 1999, 29:1033-1041. 10.1080/004982599238092.
6. Fent K., Weston A.A., Caminada D. Ecotoxicology of human pharmaceuticals. Aquat. Toxicol. 2006, 76:122-159. 10.1016/j.aquatox.2005.09.009.
7. Flesch G., Czendlik C., Renard D., Lloyd P. Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine. Drug Metab. Dispos. 2011, 39:1103-1110. 10.1124/dmd.109.030593.
8. Garnett W.R. Lamotrigine: pharmacokinetics. J. Child Neurol. 1997, 12:10-15. 10.1177/0883073897012001041.
9. Gurke R., Rossmann J., Schubert S., Sandmann T., Rößler M., Oertel R., Fauler J. Development of a SPE-HPLC-MS/MS method for the determination of most prescribed pharmaceuticals and related metabolites in urban sewage samples. J. Chromatogr. B 2015, 990:23-30. 10.1016/j.jchromb.2015.03.008.
10. Howell S.R., Husbands G.E., Scatina J.A., Sisenwine S.F. Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993, 23:349-359. 10.3109/00498259309057023.
11. Huerta-Fontela M., Galceran M.T., Ventura F. Occurrence and removal of pharmaceuticals and hormones through drinking water treatment. Water Res. 2011, 45:1432-1442. 10.1016/j.watres.2010.10.036.
12. Kaiser E., Prasse C., Wagner M., Bröder K., Ternes T.A. Transformation of oxcarbazepine and human metabolites of carbamazepine and oxcarbazepine in wastewater treatment and sand filters. Environ. Sci. Technol. 2014, 48:10208-10216. 10.1021/es5024493.
13. Kasprzyk-Hordern B. Pharmacologically active compounds in the environment and their chirality. Chem. Soc. Rev. 2010, 39:4466-4503. 10.1039/c000408c.
14. Kostich M.S., Lazorchak J.M. Risks to aquatic organisms posed by human pharmaceutical use. Sci. Total Environ. 2008, 389:329-339. 10.1016/j.scitotenv.2007.09.008.
15. Lajeunesse A., Smyth S.A., Barclay K., Sauvé S., Gagnon C. Distribution of antidepressant residues in wastewater and biosolids following different treatment processes by municipal wastewater treatment plants in Canada. Water Res. 2012, 46:5600-5612. 10.1016/j.watres.2012.07.042.
16. Leclercq M., Mathieu O., Gomez E., Casellas C., Fenet H., Hillaire-Buys D. Presence and fate of carbamazepine, oxcarbazepine, and seven of their metabolites at wastewater treatment plants. Arch. Environ. Contam. Toxicol. 2009, 56:408-415. 10.1007/s002440089202x.
17. López-Serna R., Petrović M., Barceló D. Occurrence and distribution of multi-class pharmaceuticals and their active metabolites and transformation products in the Ebro river basin (NE Spain). Sci. Total Environ. 2012, 440:280-289. 10.1016/j.scitotenv201206027.
18. López-Serna R., Kasprzyk-Hordern B., Petrović M., Barceló D. Multi-residue enantiomeric analysis of pharmaceuticals and their active metabolites in the Guadalquivir River basin (South Spain) by chiral liquid chromatography coupled with tandem mass spectrometry, in: analytical and bioanalytical. Chemistry 2013, 5859-5873. 10.1007/s0021601369007.
19. Majewsky M., Gallé T., Bayerle M., Goel R., Fischer K., Vanrolleghem P.a Xenobiotic removal efficiencies in wastewater treatment plants: residence time distributions as a guiding principle for sampling strategies. Water Res. 2011, 45:6152-6162. 10.1016/j.watres201109005.
20. Martínez Bueno M.J., Gomez M.J., Herrera S., Hernando M.D., Agüera A., Fernández-Alba A.R. Occurrence and persistence of organic emerging contaminants and priority pollutants in five sewage treatment plants of Spain: two years pilot survey monitoring. Environ. Pollut. 2012, 164:267-273. 10.1016/j.envpol201201038.
21. Marx C., Mühlbauer V., Schubert S., Oertel R., Ahnert M., Krebs P., Kuehn V. Representative input load of antibiotics to WWTPs: predictive accuracy and determination of a required sampling quantity. Water Res. 2015, 76:19-32. 10.1016/j.watres201502049.
22. Metcalfe C.D., Koenig B.G., Bennie D.T., Servos M., Ternes T.A., Hirsch R. Occurrence of neutral and acidic drugs in the effluents of Canadian sewage treatment plants. Environ. Toxicol. Chem. 2003, 22:2872-2880. 10.1897/02469.
23. Metcalfe C.D., Chu S., Judt C., Li H., Oakes K.D., Servos M.R., Andrews D.M. Antidepressants and their metabolites in municipal wastewater, and downstream exposure in an urban watershed. Environ. Toxicol. Chem. 2010, 29:79-89. 10.1002/etc27.
24. Mompelat S., Le Bot B., Thomas O. Occurrence and fate of pharmaceutical products and by-products, from resource to drinking water. Environ. Int. 2009, 35:803-814. 10.1016/j.envint200810008.
25. Oertel R., Schubert S., Mühlbauer V., Büttner B., Marx C., Kirch W. Determination of clindamycin and its metabolite clindamycin sulfoxide in diverse sewage samples. Environ. Sci. Pollut. Res. Int. 2014, 21:11764-11769. 10.1007/s1135601323332.
26. Ort C., Lawrence M.G., Rieckermann J., Joss A. Sampling for pharmaceuticals and personal care products (PPCPs) and illicit drugs in wastewater systems: are your conclusions valid? A critical review. Environ. Sci. Technol. 2010, 44:6024-6035. 10.1021/es100779n.
27. Petrie B., Barden R., Kasprzyk-Hordern B. A review on emerging contaminants in wastewaters and the environment: current knowledge, understudied areas and recommendations for future monitoring. Water Res. 2014, 10.1016/j.watres.2014.08.053.
28. Petrovic M. Methodological challenges of multi-residue analysis of pharmaceuticals in environmental samples. Trends Environ. Anal. Chem. 2014, 1:e25-e33. 10.1016/j.teac.2013.11.004.
29. Rao C.R., Miller J.P., Rao D.C. Handbook of Statistics: Epidemiology and Medical Statistics 2007, Elsevier. 27th ed.
30. Rouan M.C., Lecaillon J.B., Godbillon J., Menard F., Darragon T., Meyer P., Jungers P., Kourilsky O., Hillion D., Aldigier J.C. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur. J. Clin. Pharmacol. 1994, 47:161-167. 10.1007/BF00194967.
31. Rúa-Gómez P.C., Püttmann W. Occurrence and removal of lidocaine, tramadol, venlafaxine, and their metabolites in German wastewater treatment plants. Environ. Sci. Pollut. Res. Int. 2012, 19:689-699. 10.1007/s11356-011-0614-1.
32. Santos L.H.M., Araújo A.N., Fachini A., Pena A., Delerue-Matos C., Montenegro M.C.B. Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment. J. Hazard. Mater. 2010, 175:45-95. 10.1016/j.jhazmat.2009.10.100.
33. Schaber G., Stevens I., Gaertner H.J., Dietz K., Breyer-Pfaff U. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br. J. Clin. Pharmacol. 1998, 46:453-459.
34. Schütz H., Feldmann K.F., Faigle J.W., Kriemler H.-P., Winkler T. The metabolism of 14 C-oxcarbazepine in man. Xenobiotica 1986, 16:769-778. 10.3109/00498258609043567.
35. Sheehan J.J., Sliwa J.K., Amatniek J.C., Grinspan A., Canuso C.M. Atypical antipsychotic metabolism and excretion. Curr. Drug Metab. 2010, 11:516-525. 10.2174/138920010791636202.
36. Szegedi A., Schwertfeger N. Mirtazapine: a review of its clinical efficacy and tolerability. Expert. Opin. Pharmacother. 2005, 6:631-641. 10.1517/14656566.6.4.631.
37. Timmer C.J., Sitsen J.M., Delbressine L.P. Clinical pharmacokinetics of mirtazapine. Clin. Pharmacokinet. 2000, 38:461-474. 10.2165/00003088-200038060-00001.
38. Valcárcel Y., Alonso S.G., Rodríguez-Gil J.L., Maroto R.R., Gil A., Catalá M. Analysis of the presence of cardiovascular and analgesic/anti-inflammatory/antipyretic pharmaceuticals in river- and drinking-water of the Madrid Region in Spain. Chemosphere 2011, 82:1062-1071. 10.1016/j.chemosphere.2010.10.041.
39. Verlicchi P., Al Aukidy M., Zambello E. Occurrence of pharmaceutical compounds in urban wastewater: removal, mass load and environmental risk after a secondary treatment - a review. Sci. Total Environ. 2012, 429:123-155. 10.1016/j.scitotenv.2012.04.028.
40. Vieno N., Tuhkanen T., Kronberg L. Elimination of pharmaceuticals in sewage treatment plants in Finland. Water Res. 2007, 41:1001-1012. 10.1016/j.watres.2006.12.017.
41. Wynalda M.A., Hutzler J.M., Koets M.D., Podoll T., Wienkers L.C. In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab. Dispos. 2003, 31:878-887. 10.1124/dmd.31.7.878.